指南与共识泌尿生殖与妇科肿瘤放疗放疗物理与技术

验证NRG盆腔淋巴结与GFRU前列腺床勾画指南在前列腺切除术后挽救放疗中的覆盖效能:LOCATE试验二次分析

Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2021-05-17

该研究基于LOCATE试验中前列腺切除术后生化复发且18F-fluciclovine PET/CT阳性患者的复发模式,对比评估2020年NRG盆腔淋巴结指南与2020年GFRU前列腺床指南相较于旧版RTOG指南对复发灶的覆盖情况。结果显示GFRU前列腺床指南覆盖90%复发灶(旧版RTOG为67%),NRG盆腔淋巴结指南覆盖100%淋巴结复发灶(旧版RTOG为67%)。

要点

  • 2020 GFRU前列腺床勾画指南覆盖90%的前列腺床复发灶,优于2010 RTOG的67%。
  • 2020 NRG盆腔淋巴结勾画指南覆盖100%的淋巴结复发灶,优于2009 RTOG的67%。
  • 基于PET复发模式验证,新版指南较旧版显著提高复发灶完全覆盖比例。

核心结论

  • GFRU 2020前列腺床勾画指南较2010 RTOG指南提高了前列腺床复发灶的覆盖比例。
  • NRG 2020盆腔淋巴结勾画指南较2009 RTOG指南实现了对淋巴结复发灶的完全覆盖,验证了其更新价值。

研究设计与样本

  • LOCATE试验的二次分析,纳入根治性前列腺切除术后生化复发且18F-fluciclovine PET/CT在前列腺床或盆腔淋巴结阳性患者。
  • 从LOCATE试验213例患者中筛选出45例符合分析条件者。
  • 分别用2010 RTOG与2020 GFRU指南勾画前列腺床,用2009 RTOG与2020 NRG指南勾画盆腔淋巴结,评估对大体复发灶的覆盖比例。

主要发现

  • 30个前列腺床复发灶中,2010 RTOG轮廓完全覆盖20个(67%),遗漏或边缘覆盖10个(33%)。
  • 30个前列腺床复发灶中,2020 GFRU轮廓完全覆盖27个(90%),遗漏或边缘覆盖3个(10%)。
  • 43个淋巴结复发灶中,2009 RTOG盆腔淋巴结轮廓完全覆盖29个(67%),遗漏或边缘覆盖14个(32%)。
  • 43个淋巴结复发灶中,2020 NRG盆腔淋巴结轮廓完全覆盖43个(100%),无遗漏或边缘覆盖。

关键数值与推荐

  • 2020 GFRU前列腺床勾画指南:覆盖90%前列腺床复发灶,遗漏或边缘覆盖10%。
  • 2020 NRG盆腔淋巴结勾画指南:覆盖100%淋巴结复发灶,无遗漏或边缘覆盖。
  • 2010 RTOG前列腺床指南覆盖67%、2009 RTOG盆腔淋巴结指南覆盖67%,均低于新版指南。

临床怎么用

  • 在前列腺切除术后挽救性放疗中,可优先采用2020 GFRU前列腺床勾画指南以提高复发灶覆盖。
  • 盆腔淋巴结勾画可采用2020 NRG指南,因其对PET阳性淋巴结复发灶实现完全覆盖。
  • 基于18F-fluciclovine PET复发模式验证的结果,支持在临床实践中更新勾画标准。

局限性

  • 本研究为LOCATE试验的二次分析,样本量有限(45例可分析患者)。
  • 复发灶基于18F-fluciclovine PET/CT显像定义,未涉及其他影像或病理验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We used the patterns of recurrence on 18F-fluciclovine positron emission tomography (PET)-computed tomography (CT) in patients enrolled in the LOCATE trial after prostatectomy to evaluate how well the most recent NRG Oncology and Groupe Francophone de Radiothérapie Urologique (GFRU) contouring recommendations encompassed all sites of recurrence in the prostate fossa and pelvic nodes in comparison to former Radiation Therapy Oncology Group (RTOG) recommendations. METHODS AND MATERIALS: Patients with biochemically recurrent prostate cancer after radical prostatectomy with a positive finding within the prostate fossa or pelvic nodes on 18F-fluciclovine PET/CTs were identified from the LOCATE patient population. Areas of gross disease were delineated. Prostate fossa contours were delineated using both the 2010 RTOG consensus guidelines and the recently published 2020 GFRU consensus guidelines. Pelvic nodes were contoured with both the 2009 RTOG consensus guidelines and the 2020 NRG consensus guidelines. The performance of the contouring guidelines was assessed by determining what proportion of gross recurrent lesions were encompassed completely or marginally. RESULTS: Of the 213 patients within the LOCATE trial, 45 patients were eligible for analysis with positive 18F-fluciclovine PET findings. Of the 30 total prostate fossa recurrences, the 2010 RTOG contour covered 20 (67%) and missed or marginally covered 10 (33%). The 2020 GFRU contour covered 27 recurrences (90%), and missed or marginally covered 3 (10%). Of the 43 total nodal recurrences, the 2009 RTOG pelvic nodal contour covered 29 nodes (67%), and missed or marginally covered 14 (32%). The 2020 NRG pelvic nodal contour covered 43 nodes (100%), with no misses or marginal coverage. CONCLUSIONS: This secondary analysis of the LOCATE trial exemplifies the improved coverage of the latest prostate fossa contouring recommendations from the GFRU. Similarly, it also validates the updated 2020 NRG pelvic nodal contouring guidelines by demonstrating improved coverage of recurrent disease in this patient population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Harmon G, Chan D, Lee B, et al. Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 34015368. doi:10.1016/j.ijrobp.2021.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。